• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    B

    Barrie Urology Group

    EST. 2003
    34论文总数
    700引用总数

    论文量&引用量时间轴

    机构学者

    论文(34)

    年份
    起
    –
    止
    排序
    1Open-label Treatment Extension of Ruxolitinib Cream in Vitiligo: Findings from the Topical Ruxolitinib Evaluation in Vitiligo (True-V) Long-Term Extension Phase III Study.
    John E Harris,Kim Papp,Khaled Ezzedine,Michael Sebastian,Amit G Pandya,Julien Seneschal, Mark Amster, Maryam Shayesteh Alam,Seth B Forman,Jacek Zdybski, Anthony Nuara,Deanna Kornacki,

    We present data from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension (LTE) study evaluating repigmentation outcomes with continued 1.5% ruxolitinib cream treatment in patients who did not achieve near-complete facial repigmentation in TRuE-V1/TRuE-V2. Among patients in the TRuE-V1/TRuE-V2 trials who applied ruxolitinib cream from day 1, approximately 66% achieved F-VASI 75 (indicative of treatment success) at week 104, increasing from nearly 31% at week 52 (TRuE-V LTE baseline); similar repigmentation improvements were reported in patients who switched from vehicle to ruxolitinib cream after TRuE-V1/TRuE-V2 at week 24, albeit with lower overall response rates due to the shorter duration of ruxolitinib cream application. These findings indicate that continued ruxolitinib cream treatment allows further repigmentation in many patients.

    2026The British journal of dermatology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2Multivitamins after Myocardial Infarction in Patients with Diabetes
    Francisco Ujueta,Gervasio A. Lamas,Kevin J. Anstrom,Ana Navas-Acien,Robin Boineau,Yves Rosenberg,Mario Stylianou,Teresa L. Z. Jones,Bonnie R. Joubert,Qilu Yu, Jun Wen, Hayley Nemeth,

    In 2013, the Trial to Assess Chelation Therapy (TACT) reported that in 1708 patients with stable coronary disease and prior myocardial infarction (MI), oral multivitamins and multiminerals (OMVMs), in a factorial design with edetate disodium (EDTA) chelation therapy, did not reduce cardiovascular events relative to placebo OMVMs, but active EDTA combined with active OMVMs was superior to placebo OMVM/placebo EDTA. To compare OMVM vs placebo in terms of efficacy for reducing major adverse cardiovascular events in patients with diabetes and prior MI. The TACT2 randomized, multicenter double-masked 2 × 2 factorial clinical trial took place across 88 sites in the US and Canada. Participants were 50 years or older, had diabetes, and had an MI 6 weeks ago or more. TACT2 participants were enrolled between September 2016 and December 2020. Data were collected between October 2016 and June 2023. Six caplets daily of a 28 component OMVM or matching OMVM placebo, and 40 weekly infusions of an EDTA-based chelation solution or matching placebo, in a 1:1:1:1 allocation ratio. The primary end point was the composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. A total of 1000 participants were randomized (500 in the active OMVM group and 500 in the placebo group). The median (IQR) age was 67 (60-72) years, and 730 (73%) were male. Median (IQR) follow-up was 48 (34-58) months. The primary end point occurred in 175 participants (35%) in the active OMVM group and 175 (35%) in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.80-1.22]; P = .92). The 5-year event rate for the primary end point in the EDTA chelation + active OMVM group was 34.0%; in the EDTA chelation + placebo OMVM group, 35.7%; in the placebo infusion + active OMVM group, 36.0%; and in the placebo infusion + placebo OMVM group, 34.3%. The comparison of the active infusion + active OMVM with the placebo infusion + placebo OMVM was not significant (HR, 0.91 [95% CI, 0.67-1.23]; P = .54). Although nonsignificant, there was a numerically higher event rate of MI, stroke, mortality from cardiovascular causes in the active OMVM compared to placebo OMVM group. The results of this randomized clinical trial demonstrated that, for participants with chronic coronary disease, diabetes, and a previous MI, high-dose OMVM alone or in conjunction with EDTA-based chelation did not reduce cardiovascular events. ClinicalTrials.gov Identifier: NCT02733185

    2025JAMA Internal Medicine(2025)
    引用
    AI阅读
    加入学术空间
    3Efficacy and Safety of Azacitidine in the Treatment of Elderly Patients with Higher-Risk Myelodysplastic Syndromes.
    Nupur Krishnan, David Yanni, Leah Kogan,Ian Drennan, Lauren Gerard,Rouslan Kotchetkov

    e18578 Background: Hypomethylating agent Azacitidine (AZA) is standard of care for high-risk myelodysplastic syndromes (MDS). There is limited real-life data, however, characterizing the efficacy and safety profile of AZA in elderly patients. Methods: A retrospective chart review of high-risk MDS patients at our institution who received front-line AZA therapy. Patients who proceeded with stem cell transplant were excluded. Patients were stratified by age: ≥75 years (elderly) vs <75 years (younger) and patterns of administration, safety, and efficacy of AZA in patients were compared. Results: Among a total of 105 patients, 56 were elderly (median age 79), including 27 patients >80 years, 49 were younger (median age 69). ECOG 3 had 8.9% of older & 12.2% of younger patients. Median R-IPSS score was 6.5 in younger vs 5.8 in elderly groups. Median number of comorbidities was 5 vs 6 in younger and elderly groups. 98% of elderly and 90% of younger patients received the full dose of AZA (75mg/m2). Median number of AZA cycles was 8 [range 1-107] in elderly vs 6 [1-96] in younger cohorts. Treatment delays had 35.7% of elderly vs 30.6% of younger patients, most commonly due to infection complications. Neutropenia, thrombocytopenia and anemia rates were 29.3%, 29.2%, and 26.8% in younger vs 43.6%, 25.2%, and 34.5% in older patients. Overall response rate was 92.8% in younger and 96.4% of elder patients, including complete remission in 53.7% and 58.3%, respectively. Relapse disease occurred in 48.8% of younger and 40.0% of elder patients. Transformation to AML was found in 9.8% of younger and 19.2% of elderly patients. Median OS was 17.3 months in the younger subgroup vs 15.7 in the elder group and 11.9 months in patients over 80 years. Rates of death were: 53.1% in younger vs 46.4% in the elderly. Causes of death were similar, including disease progression, sepsis, febrile neutropenia, pneumonia. Conclusions: AZA monotherapy is well-tolerated and effective in higher-risk MDS, even in very elderly patients (>80 years). Compared to clinical trial, patients in the real-world setting have shorter survival, higher ECOG status, and more comorbidities, potentially contributing to inferior outcomes. Clinical and hematological responses. Efficacy parameter/Age cohort, years (N) <75 (49) ≥75 (56) p value Hematological Response (median [min-max]) Baseline Hemoglobin (g/L) 77 [46-100] 80 [56-140] 0.014 Best Hemoglobin achieved on AZA (g/L) 103 [74-152] 108 [70-155] NS Baseline ANC (x10 9 /L) 0.7 [0-27] 0.89 [0.02-58] NS Best ANC achieved on AZA (x10 9 /L) 1.4 [0.02-12.3] 2.2 [0.04-9.6] 0.047 Baseline platelet count (x10 9 /L) 49 [2-600] 57 [16-558] 0.029 Best achieved on AZA (x10 9 /L) 128 [21-474] 155 [10-767] NS Transformation to AML N, (%) 4 (9.8) 10 (18.2) NS Reached transfusion independence, N (%) 30 (61.0) 38 (67.2) NS Response rate, N (%) ORR 46 (92.8) 54 (96.4) NS Complete Response 26 (53.7) 33 (58.2) NS Partial Response 11 (22.0) 11 (20.0) NS Stable Disease 8 (17.1) 10 (18.2) NS Mean Leukemia Free Survival (years) 1.13 1.05 NS Mean Overall Survival (years) 1.14 1.05 NS

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    4From the Society of Captives to the Flourishing Society: the Appeal to Aristotelian Virtue Ethics
    Eli Remington
    2023Bruce Arrigo(2023)
    引用
    AI阅读
    加入学术空间
    5Applying a Cannabis Impairment Framework to Medical Cannabis Patients
    Caroline A. MacCallum,April L. Christiansen,Lindsay A. Lo,Carly A. Pistawka, Michael Boivin,Melissa Snider-Adler

    The increasing prevalence and acceptance of medical cannabis necessitate that clinicians be able to assess and mitigate the risk of acute cannabis impairment in their patients during day-to-day operations and safety-sensitive tasks. However, assessing the level of impairment risk is challenging as there are a number of patient- and cannabis-specific determinants of impairment and an absence of practical tools or established methods available to help effectively evaluate this risk. To address this cardinal issue, a novel, evidence-informed framework is presented and applied to a complex patient case to demonstrate how clinicians can comprehensively assess impairment risk in patients using or considering medical cannabis. Such assessments can inform patient-specific needs for support, education, and guidance, as well as promote the safe and responsible use of cannabis in daily operations, safety-sensitive positions, and therapeutic contexts.

    2023Medicinal Usage of Cannabis and Cannabinoids(2023)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 34 篇论文

    合作机构(53)

    不列颠哥伦比亚大学合作论文 3
    Queen''s University合作论文 3
    Public Health Ontario合作论文 2
    加齐大学合作论文 2
    Massachusetts General Hospital,Harvard Medical School合作论文 2
    兰利研究中心合作论文 1
    利默里克大学合作论文 1
    大气科学研究大学联盟合作论文 1
    Université Côte d''Azur合作论文 1
    麦克马斯特大学合作论文 1

    机构统计